Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)GlobeNewsWire • 03/17/20
Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial OfficerGlobeNewsWire • 03/12/20
Karyopharm Therapeutics - Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/09/20
Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 03/06/20
Karyopharm's stock jumps on trial results for multiple myeloma combo candidateMarket Watch • 03/02/20
This Biotech Stock Broke Out As A Cancer Drug 'Transforms' Its StoryInvestors Business Daily • 03/02/20
Do Options Traders Know Something About Karyopharm (KPTI) Stock We Don't?Zacks Investment Research • 02/27/20
Karyopharm Therapeutics Inc. (KPTI) CEO Michael Kauffman on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/13/20
Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in IsraelGlobeNewsWire • 02/11/20
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewsWire • 02/03/20
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4).GlobeNewsWire • 01/02/20
Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaGlobeNewsWire • 12/23/19
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual MeetingGlobeNewsWire • 12/07/19
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4).GlobeNewsWire • 12/02/19